IP Library Granted Patent US 10,214,547
Granted Patent B2
US 10,214,547 · App. 15/787,224 · Granted Feb 26, 2019

Beta-lactamase inhibitors

Inventors: Christopher J. Burns (Malvern, PA); Denis Daigle (Street, MD); Bin Liu (Plainsboro, NJ); Daniel McGarry (Malvern, PA); Daniel C. Pevear (Downingtown, PA); Robert E. Lee Trout (Collegeville, PA)
Assignee: VENATORX PHARMACEUTICALS, INC.
C07F5/025A61K9/0019A61K9/0053A61K31/69A61K45/06C07F5/027C07F5/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,214,547
App. No.
15/787,224
Granted
Feb 26, 2019
Kind
B2
Abstract

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

Claims (12)

1. A compound represented by the following structures, or a stereoisomer thereof:

2. The compound of claim 1 , wherein the compound is represented by the following structure:

3. A pharmaceutical composition comprising a compound of claim 1 or 2 ; and a pharmaceutically acceptable excipient.

4. The pharmaceutical composition of claim 3 , further comprising a beta-lactam antibiotic.

5. The pharmaceutical composition of claim 4 , wherein the beta-lactam antibiotic is a penicillin, cephalosporin, carbapenem, monobactam, bridged monobactam, or a combination thereof.

6. A pharmaceutically acceptable salt of a compound represented by the following structures, or a stereoisomer thereof:

or a solvate thereof.

7. The pharmaceutically acceptable salt of claim 6 , wherein the compound is represented by the following structure:

or a solvate thereof.

8. A pharmaceutical composition comprising a pharmaceutically acceptable salt of claim 6 or 7 ; and a pharmaceutically acceptable excipient.

9. The pharmaceutical composition of claim 8 , further comprising a beta-lactam antibiotic.

10. The pharmaceutical composition of claim 9 , wherein the beta-lactam antibiotic is a penicillin, cephalosporin, carbapenem, monobactam, bridged monobactam, or a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2017
From: BURNS, CHRISTOPHER J.; DAIGLE, DENIS; LIU, BIN; MCGARRY, DANIEL; PEVEAR, DANIEL C.; TROUT, ROBERT E. LEE
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 044227/0562 →
Continuity (5)
Continuation 15212959 · Jul 18, 2016
Continuation 14649527
Provisional Application 61734900 · Dec 7, 2012
Provisional Application 61783238 · Mar 14, 2013
Related Publication 20180194783A1 · Jul 12, 2018
Cited By (3)
US 12,187,752 US 12,544,395 US 12,606,573